Gate.io 10月22日,Samsung Bio announced today that it has reached a production agreement with an Asian pharmaceutical company. The contract value disclosed this time is $1.24 billion, which is the largest contract signed by a single customer. Production will be carried out at Samsung Bio’s biomanufacturing base in Songdo, South Korea, and the contract will last until December 2037. With the signing of the latest protocol, the company’s cumulative contract amount for 2024 has exceeded $3.3 billion.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Samsung Biologics ve Asya İlaç Şirketi, 12.4 milyar dolarlık bir protokol üretimi için anlaşma imzaladı.
Gate.io 10月22日,Samsung Bio announced today that it has reached a production agreement with an Asian pharmaceutical company. The contract value disclosed this time is $1.24 billion, which is the largest contract signed by a single customer. Production will be carried out at Samsung Bio’s biomanufacturing base in Songdo, South Korea, and the contract will last until December 2037. With the signing of the latest protocol, the company’s cumulative contract amount for 2024 has exceeded $3.3 billion.